[HTML][HTML] Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal …

KP Rovers, C Bakkers, GAAM Simkens, JWA Burger… - Bmc Cancer, 2019 - Springer
Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard
treatment for isolated resectable colorectal peritoneal metastases (PM) in the Netherlands …

Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a …

KP Rovers, C Bakkers, SW Nienhuijs, JWA Burger… - JAMA …, 2021 - jamanetwork.com
Importance To date, no randomized clinical trials have investigated perioperative systemic
therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy …

Acute malignant obstruction in patients with peritoneal carcinomatosis: the role of palliative surgery

NL de Boer, JAW Hagemans, BTA Schultze… - European Journal of …, 2019 - Elsevier
Introduction Patients with peritoneal carcinomatosis who do not have curative treatment
options often develop acute obstructive symptoms and when conservative management …

[HTML][HTML] The accuracy of the surgical peritoneal cancer index in patients with peritoneal metastases of colorectal cancer

NL De Boer, ARM Brandt-Kerkhof, EVE Madsen… - Digestive …, 2021 - karger.com
Introduction: The peritoneal cancer index (PCI) is one of the most important prognostic
factors in patients with peritoneal metastases from colorectal cancer undergoing …

[HTML][HTML] Malignant peritoneal mesothelioma: patterns of care and survival in the Netherlands: a population-based study

NL de Boer, JP van Kooten, RAM Damhuis… - Annals of Surgical …, 2019 - Springer
Background Malignant peritoneal mesothelioma (MPM) is a rare and aggressive disease.
Recently, focus has shifted toward a more aggressive and multimodal treatment approach …

Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases

RAG van Eerden, NL de Boer… - British Journal of …, 2023 - academic.oup.com
Background Patients with colorectal peritoneal metastases who are not eligible for
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) owing …

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal …

NL de Boer, JP van Kooten, JWA Burger, C Verhoef… - BMJ open, 2019 - bmjopen.bmj.com
Introduction Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive
neoplasm and has a strong association with asbestos exposure. MPM has low survival rates …

[HTML][HTML] Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal …

MV Dietz, KLA Quintelier, JP van Kooten… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Malignant peritoneal mesothelioma (MPM) is an aggressive malignancy with a
poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal …

Short-term complications in elderly patients undergoing CRS and HIPEC: a single center's initial experience

A Oemrawsingh, NL de Boer… - European Journal of …, 2019 - Elsevier
Introduction Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) is a well-established curative treatment for patients with peritoneal carcinomatosis …

[HTML][HTML] Predictive ability of C-reactive protein in detecting short-term complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a …

JP Van Kooten, A Oemrawsingh, NL de Boer… - Annals of Surgical …, 2021 - Springer
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy
(HIPEC) is a potentially curative treatment for peritoneal carcinomatosis. Objective The aim …